文献速递血液净化与透析

中国透析治疗肾病患病率估算:保险理赔数据研究

Estimation of Prevalence of Kidney Disease Treated With Dialysis in China: A Study of Insurance Claims Data.
PubMed 文献 · Am J Kidney Dis · 2021-01-07

本研究基于2013至2017年中国城市基本医疗保险理赔数据,采用两阶段抽样设计,估算维持性透析的年龄和性别标准化患病率。结果显示标准化患病率从2013年的255.11 pmp升至2017年的419.39 pmp,预测2020年达534.60 pmp、2025年达629.67 pmp。研究提示中国透析患者负担持续上升,需加强防控策略。

要点

  • 2017年中国透析标准化患病率为419.39 pmp,患者总数估计581,273例。
  • 2013至2017年标准化患病率从255.11 pmp增至419.39 pmp。
  • 预测2020年患病率534.60 pmp、2025年629.67 pmp,患者数分别达744,817和874,373例。

核心结论

  • 中国透析治疗肾病患病率在2013至2017年间上升,并预测至2025年进一步增加,需重视防控策略以减轻肾衰竭负担。

研究设计与样本

  • 基于保险理赔数据的横断面研究,采用两阶段抽样设计从大型理赔数据库提取2013年1月1日至2017年12月31日城市基本医疗保险数据。

主要发现

  • 年龄和性别标准化透析患病率从2013年255.11 pmp增至2017年419.39 pmp。
  • 2017年血液透析和腹膜透析标准化患病率分别为384.41 pmp和34.98 pmp,透析患者总数估计581,273例。
  • 预测2020年患病率534.60 pmp(744,817例),2025年629.67 pmp(874,373例)。

关键数值与推荐

  • 透析患者根据医疗账单数据和ICD-10编码识别,包括血液透析和腹膜透析。
  • 使用灰色Verhulst模型预测2018至2025年透析患病率。

临床怎么用

  • 研究结果可为制定肾衰竭预防和控制策略提供依据,以应对透析负担的持续上升。

局限性

  • 理赔数据在患者分类上可能存在错误,人群选择偏倚可能限制对整个中国人群的推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The national prevalence of dialysis in China has not been well studied. We aimed to estimate the prevalence of kidney disease treated with dialysis and predict the trend using claims data in order to provide evidence for developing prevention strategies. STUDY DESIGN: Cross-sectional study of insurance claims. SETTING & PARTICIPANTS: Medical claims data from January 1, 2013, to December 31, 2017, were extracted from a large claims database by using a 2-stage sampling design to obtain a national sample covered by the urban basic medical insurance, the most predominant insurance program in China. EXPOSURE: Patients receiving maintenance dialysis, including hemodialysis (HD) and peritoneal dialysis (PD), were identified according to medical billing data and International Classification of Diseases, Tenth Revision (ICD-10) codes. OUTCOMES: The age- and sex-standardized population prevalence of kidney disease treated with dialysis was estimated by year and treatment modality. ANALYTICAL APPROACH: Crude and age- and sex-standardized prevalence of kidney disease treated with dialysis were calculated stratified by year and treatment modality. The gray Verhulst model was used to predict dialysis prevalence from 2018 to 2025. RESULTS: The age-and sex-standardized prevalence of dialysis patients increased from 255.11 per million population (pmp) in 2013 to 419.39 pmp in 2017. The age- and sex-standardized prevalence of HD and PD in 2017 were 384.41 pmp and 34.98 pmp, respectively, and the total number of dialysis patients in China was estimated to be 581,273. The prevalence of dialysis was predicted to rise above 2017 levels, with a predicted prevalence of 534.60 pmp in 2020 and 629.67 pmp in 2025, corresponding to 744,817 and 874,373 patients, respectively. LIMITATIONS: Claims data have potential errors in classification of patients, and population selection bias may have limited inferences to the entire Chinese population. CONCLUSIONS: The prevalence of kidney disease treated with dialysis has risen between 2013 and 2017 in China and is predicted to increase further through 2025. These findings highlight the importance of prevention and control strategies to reduce the escalating burden of kidney failure.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yang C, Yang Z, Wang J, et al. Estimation of Prevalence of Kidney Disease Treated With Dialysis in China: A Study of Insurance Claims Data. Am J Kidney Dis. 2021. PMID: 33421457. doi:10.1053/j.ajkd.2020.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。